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ABSTRACT
Objective Assess whether statins reduce mortality in the 
general population aged 60 years and above.
Design Retrospective cohort study.
Setting Primary care practices contributing to The Health 
Improvement Network database, England and Wales, 
1990–2017.
Participants Cohort who turned age 60 between 1990 
and 2000 with no previous cardiovascular disease or statin 
prescription and followed up until 2017.
Results Current statin prescription was associated with 
a significant reduction in all- cause mortality from age 
65 years onward, with greater reductions seen at older 
ages. The adjusted HRs of mortality associated with statin 
prescription at ages 65, 70, 75, 80 and 85 years were 0.76 
(95% CI 0.71 to 0.81), 0.71 (95% CI 0.68 to 0.75), 0.68 
(95% CI 0.65 to 0.72), 0.63 (95% CI 0.53 to 0.73) and 0.54 
(95% CI 0.33 to 0.92), respectively. The adjusted HRs did 
not vary by sex or cardiac risk.
Conclusions Using regularly updated clinical information 
on sequential treatment decisions in older people, 
mortality predictions were updated every 6 months until 
age 85 years in a combined primary and secondary 
prevention population. The consistent mortality reduction 
of statins from age 65 years onward supports their use 
where clinically indicated at age 75 and older, where there 
has been particular uncertainty of the benefits.
INTRODUCTION
Cardiovascular disease (CVD) is the biggest 
cause of death from non- communicable 
disease in the world.1 Clinical guidelines 
internationally recommend statin therapy 
for both primary and secondary preven-
tion of CVD, making statins one of the most 
frequently prescribed drugs in industrialised 
countries.2–5 Yet uncertainty remains about 
the benefits of statin therapy in older people, 
particularly those aged 75 years or older 
who do not have a history of CVD, due to 
relatively few older people being included 
in randomised controlled trials (RCTs).6–8 
In 2019, the Cholesterol Treatment Trial-
ists’ Collaboration published a meta- analysis 
of 28 randomised trials of statin therapy in 
older people. They found a trend towards 
smaller relative reductions in cardiac events 
and vascular mortality with increasing age, 
and no effect on non- vascular mortality.9 
Their risk ratios, however, were inappropri-
ately presented as per mmol/L reduction in 
low- density lipoprotein (LDL, ‘bad choles-
terol’), making it difficult to compare with 
findings of other studies, and their data 
have not been made available for scrutiny. A 
recent meta- analysis of RCTs and a contem-
porary cohort showed the efficacy of LDL 
lowering treatment for primary prevention of 
cardiovascular events for patients aged 75 or 
older.10 11 However, another study found that 
low and high levels of LDL was associated 
with increased risk of all- cause mortality, ques-
tioning the safety of cholesterol- lowering.12 
The persistent uncertainty about the bene-
fits and risks of statins in those aged over 
75 is being addressed by trials including the 
STAREE trial, which is examining whether 
statin therapy will reduce all- cause mortality 
Key points
Question
 ► Current guidelines on the prevention of cardiovas-
cular disease are cautious with recommending sta-
tin therapy to people aged 75 years or older due to 
the limited evidence from clinical trials of the over-
all benefit in this group. This study aimed to clarify 
whether current statin prescription reduces mortali-
ty in the older population, with updated survival pre-
dictions every six months from age 60 to 85 years 
reflecting fluid clinical practice.
Finding
 ► Current statin prescription was associated with sig-
nificant absolute and relative reduction in mortality 
at older ages, including those aged 75 years or older, 
irrespective of sex and cardiac risk.
Meaning
 ► This supports the use of statins in those aged 75 
years or older, where clinically indicated and after 
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among healthy older people (≥70 years), with an esti-
mated study completion date of December 2023.13
A limitation of RCTs, however, is that they tend to be 
of relatively short duration, with the CTT trials having a 
median follow- up of almost 5 years9 and STAREE planned 
to have an average of 5- year treatment period,13 whereas 
statins are usually prescribed for life. This means that still 
little is known about the long- term overall effects of statin 
therapy. Furthermore, in the clinical practice, patients 
are not fixed on a certain treatment regime as during an 
RCT but instead sequential treatment decisions are made 
in managing their changing cardiac risk.14
We previously studied the long- term survival benefit of 
a history of statin prescription for primary prevention of 
CVD, without taking into account time- varying covariates, 
and found a significant reduction in all- cause mortality 
from age 65 onward.15 Whereas a recent study showed 
that current but not former use of statins for primary 
prevention of CVD is effective in people aged 75 years 
and older.16 Our study assessed whether current statin 
prescription for primary and secondary prevention of 
CVD reduces mortality in the general population, with 
updated survival predictions every 6 months from age 60 
to 85 years reflecting fluid clinical practice.
METHODS
Study design
A retrospective cohort study was designed using EHR 
from The Health Improvement Network (THIN) primary 
care database. THIN records are broadly representa-
tive of the UK population prevalence of medical condi-
tions and mortality rates when adjusted for sex, age and 
deprivation.17 18 The study recruitment period was from 
January 1990 to December 2000. The start of the study 
period was chosen to be approximately 2 years after the 
first commercial statin was approved by health authori-
ties,19 to ensure that the therapy would be available to the 
study population. The follow- up period was to January 
2017 with medical history updated every 6 months.
The cohort included patients who, at baseline, were 
aged 60, residential in England or Wales and had no 
medical history of statin therapy nor CVD as defined by 
QRISK researchers (coronary heart disease and cerebro-
vascular disease, but not peripheral vascular disease).20 
This allowed to study new statins users for primary 
prevention of CVD and, as a proportion of patients was 
expected to develop CVD and be prescribed statins 
during follow- up, also secondary prevention. As clin-
ical guidelines on statin therapy and its uptake in clin-
ical practice changed rapidly after its introduction to 
the world market, we distinguished two birth cohorts of 
patients born in 1930–1935 and 1936–40.21
Covariates
The outcome was time to all- cause mortality, which 
encompasses both benefits (eg, reduction in CVD deaths) 
and adverse events (eg, increased competing mortality). 
The exposure was statin therapy, which was measured as a 
current prescription (yes/no).
Covariates adjusted for were sex, birth cohort, cardiac 
risk, chronic kidney disease (CKD), diabetes, treated 
hypertension, hypercholesterolaemia, body mass index 
(BMI), aspirin prescription, alcohol consumption, 
smoking, Townsend deprivation quintile and general 
practice (online supplemental table S1).15 22–25 Cardiac 
risk was categorised as low, medium and high corre-
sponding to a QRISK2 score of <20%, 20%–39% and 
≥40% or CVD diagnosis, respectively. As in our previous 
paper,15 QRISK2 scores were calculated using the infor-
mation on age, sex, Townsend deprivation score, CKD, 
diabetes, systolic blood pressure (SBP), treated hyperten-
sion, hypercholesterolaemia, BMI and smoking.
There were missing values in SBP, BMI, alcohol 
consumption and smoking, which were less common 
in women (up to age 75), at older ages, in diagnosed 
or prescribed patients, and later calendar years (online 
supplemental table S2). At baseline, 63% of the sample 
had at least one missing item, which was dealt with by 
multiple imputations of 10 datasets26 27 (online supple-
mental figure S1). Missing data after baseline were dealt 
with by last observation carried forward.28
Statistical analyses
A Cox regression model was fitted to estimate the hazard 
of all- cause mortality associated with current statin 
prescription. This was done for follow- up times of 5, 10 
and 25 years and fitted every 6 months from age 60 to 
85 years, creating a sliding time window. This technique 
is called landmarking where the latest medical history is 
used at the new time point (‘landmark’) conditional on 
survival to that point, thereby allowing for time- dependent 
covariates and mortality effects, and predictions beyond 
the study period.28 The advantage of this technique 
over time- dependent Cox regression is its transparency 
of what is being compared at each time point while the 
inferences of the latter are only valid if the value of the 
time- dependent covariate is observed for all subjects at all 
event time points.29
The landmarking modelling process is explained in the 
online supplemental file 1 and more detailed in our meth-
odology paper.30 We tested for interactions of current 
statin prescription with sex, birth cohort and cardiac risk, 
which were included if significant at p<0.05. The model 
was assessed on the proportional hazards assumption 
and discrimination using the concordance index.31 The 
sensitivity analyses included (1) fitting the model while 
restricting the controls to only patients who were never 
prescribed statins, and (2) fitting the model on the subset 
of participants without missing data (‘complete- case anal-
ysis’). All statistical analyses were carried out in R V.3.5.0, 
except for the QRISK2 score calculation in JAVA V.10.
The 10- year HRs were translated to absolute and rela-
tive risk reduction (ARR and RRR) at key ages by various 
risk profiles to inform decision making in clinical guide-
lines.32 The profiles were stratified by sex, birth cohort, 
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cardiac risk, health status and deprivation. The incidence 
of diabetes in patients previously on or off statins prescrip-
tion was calculated at each landmark to assess the poten-
tial risk of diabetes resulting from statin therapy.
RESULTS
Study population
The study population comprised 110 243 patients ages 60 
years with 38% entering the study in 1990–1995 (born in 
1930–1935) and the remaining 62% in 1996–2000 (born 
in 1936–1940) (table 1). The median follow- up was 16.6 
years and maximum for 27 years, with 78 728 (71%) partic-
ipating at age 75 (online supplemental table S3). During 
the follow- up, the cardiac risk of the study population 
increased, largely driven by age (online supplemental table 
S4). The overall mortality rate per year during follow- up 
was 120 per 10 000 people, where death was observed in 
20% of the study population by the end of the study period.
Table 1 Characteristics of the study population
QRISK2 <20%* QRISK2=20%–39%*
Women (%) Men (%) Women (%) Men (%)
Cohort size 59 082 48 836 314 2011










Deaths during follow- up 10 152 (17%) 10 743 (22%) 152 (48%) 814 (40%)
Transferred during follow- up 15 410 (26%) 13 401 (27%) 70 (22%) 422 (21%)
Birth cohort 1930–35 23 139 (39%) 18 224 (37%) 92 (29%) 594 (30%)
  1936–40 35 943 (61%) 30 612 (63%) 222 (71%) 1417 (70%)
Deprivation First quintile 15 481 (26%) 13 681 (28%) 12 (4%) 315 (16%)
  Second quintile 13 652 (23%) 11 376 (23%) 22 (7%) 342 (17%)
  Third quintile 12 149 (21%) 9775 (20%) 37 (12%) 388 (19%)
  Fourth quintile 10 310 (17%) 8007 (16%) 80 (25%) 442 (22%)
  Fifth quintile
(most deprived)
7492 (13%) 5996 (12%) 162 (52%) 525 (26%)
CKD No 59 073 (100%) 48 835 (100%) 312 (99%) 2004 (100%)
  Diagnosed 9 (0%) 1 (0%) 2 (1%) 7 (0%)
Diabetes No 57 952 (98%) 47 973 (98%) 67 (21%) 1085 (54%)
  Diagnosed 1130 (2%) 863 (2%) 247 (79%) 926 (46%)
Hypertension No 44 411 (75%) 38 829 (80%) 54 (17%) 406 (20%)
  Diagnosed
and treated
6443 (11%) 3200 (7%) 204 (65%) 1128 (56%)
  Diagnosed
and not treated
8229 (14%) 6807 (14%) 55 (18%) 477 (24%)
SBP Mean (SD) in mm Hg 135.3 (17.33) 133.71 (16.61) 159.42 (20.11) 153.49 (17.72)
Aspirin No 58 490 (99%) 48 369 (99%) 293 (93%) 1918 (95%)
  Prescribed 592 (1%) 467 (1%) 21 (7%) 93 (5%)
HCL No 55 966 (95%) 46 127 (94%) 243 (78%) 1638 (81%)
  Diagnosed 3117 (5%) 2709 (6%) 71 (22%) 373 (19%)
BMI Healthy weight 23 281 (39%) 18 205 (37%) 50 (16%) 527 (26%)
  Overweight 22 739 (38%) 21 520 (44%) 98 (31%) 834 (41%)
  Obese 13 063 (22%) 9111 (19%) 167 (53%) 651 (32%)
Alcohol Non- current 30 922 (52%) 17 306 (35%) 136 (43%) 429 (21%)
  Current 28 160 (48%) 31 530 (65%) 178 (57%) 1582 (79%)
Smoking Non 47 000 (80%) 34 717 (71%) 63 (20%) 412 (20%)
  Ex 3984 (7%) 5644 (12%) 45 (14%) 231 (11%)
  Current 8098 (14%) 8476 (17%) 206 (66%) 1369 (68%)
*Mean across ten imputed datasets.
BMI, body mass index; CKD, chronic kidney disease; HCL, hypercholesterolaemia; SBP, systolic blood pressure.
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The proportion of current statin prescription increased 
greatly between 1995 and 2010 and roughly stabilised 
afterwards, with differences seen by cardiac risk, sex, and 
age (figure 1). In 2015, current statin prescription in 75 
year olds at low, medium and high cardiac risk was 10%, 
35% and 75%, respectively.
The cumulative years of statin prescription increased 
during the follow- up and were greater in the younger 
birth cohort (online supplemental figure S2). The median 
(IQR) statin exposure in those with a current prescrip-
tion at age 75 and born in 1930–1935 or 1936–1940 was 
4 (2-7) years or 6 (3-9) years, respectively. Approximately 
90% of patients with a current statin prescription adhered 
at least 75% of follow- up time (S3 Figure). By the end of 
the study period, 51% of the study population were never 
prescribed statins, 41% were prescribed at some age and 
stayed on statins, 6% were prescribed statins and subse-
quently stopped statins permanently and 2% initially 
stopped statins but came back on, including 0.5% who 
had four or more switches. The cumulative years of statin 
prescription in patients with no current statin prescrip-
tion at a landmark also showed minimal crossover of 
treatment (online supplemental figure S4).
All-cause mortality reductions
Current statins prescription was associated with a signif-
icant reduction in all- cause mortality from age 65 years 
onward, with greater reductions seen at older ages and in 
the youngest birth cohort (figure 2). Compared with no 
current statin prescription, a prescription at key ages 65, 
70, 75, 80 and 85 in for the youngest birth cohort (born 
in 1936–1940) was associated with 10 years HRs of 0.76 
(95% CI 0.71 to 0.81), 0.71 (95% CI 0.68 to 0.75), 0.68 
(95% CI 0.65 to 0.72), 0.63 (95% CI 0.53 to 0.73) and 
0.54 (95% CI 0.33 to 0.92) respectively. Similarly for the 
oldest birth cohort (born in 1930–1935), current statin 
prescription at key ages 65, 70, 75, 80 and 85 was asso-
ciated with 10 years HRs of 0.87 (95% CI 0.76 to 0.99), 
0.86 (95% CI 0.82 to 0.91), 0.78 (95% CI 0.74 to 0.82), 
0.73 (95% CI 0.69 to 0.78) and 0.84 (95% CI 0.69 to 1.03) 
respectively. Compared with the 10 years HRs, the 5 years 
and 25 years ones differed by no more than 5 percentage 
points and the differences were not significantly different 
(figure 2 and online supplemental table S5). There was 
no significant interaction between current statin prescrip-
tion and sex or cardiac risk.
The mortality probabilities and ARR and RRR asso-
ciated with current statin prescription are presented 
in table 2. The ARR increased with increasing age and 
cardiac risk, and was higher in men and those with poor 
health status. For example, at age 80 years, statin prescrip-
tion may prevent an average of 164 or 171 deaths per 1000 
men with poor health status at medium or high cardiac 
risk, respectively. In comparison, an average of 82 or 101 
deaths may be prevented for every 1000 men prescribed 
with the best health status at medium or high cardiac risk.
Regarding the main side effect of statins, the unad-
justed incidence of diabetes during the study period was 
initially almost three times as high in participants with 
prior statin prescription (9 in 1000) compared with those 
without (3 in 1000), but by age 85 the rate was the same (4 
in 1000) (online supplemental figure S5). The difference 
in rates was not significant in men at most ages and not 
significant in women from age 68 years onward.
The sensitivity analysis that compared participants 
currently prescribed statins to those never prescribed, 
found an opposite trend of decreasing mortality reduc-
tions by increasing age; starting with lower HRs at age 60 
years and converging to the same predicted reductions 
by age 80 years, with no significant difference between 
the main and sensitivity analyses from age 75 years 
Figure 1 Proportion of current statin prescription by cardiac risk, sex and age during the study period.
copyright.
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onward (online supplemental figure S6). In contrast, 
the complete case analysis showed very similar results to 
the main analysis, with overlapping confidence intervals 
of the HRs associated with current statin prescription 
(online supplemental table S6).
DISCUSSION
This study predicted the 5 years, 10 years and 25 years 
hazards of all- cause mortality associated with current 
statin prescription over 25 years in an older population 
of primary and secondary prevention of CVD in England 
and Wales. This was achieved by creating a so- called 
sliding window using the latest medical history known at 
a time point to update the HRs, reflecting the sequential 
treatment decisions made in primary care. Current statin 
prescription was associated with a significant reduction 
in mortality from age 65 years onward. The reduction 
increased by age with at least an HR of 0.68 in people 
aged 75 or older. The sensitivity analysis of comparing 
benefits of current statin prescription to no prescription 
ever found greater reductions in mortality at younger 
ages yet similar reductions in people aged 75 or older. 
Both analyses are useful in routine clinical practice as 
the main analysis answers the question what the overall 
benefit is of statin uptake now compared with potential 
future uptake, whereas the sensitivity analysis answers 
Figure 2 Adjusted HRs of all- cause mortality associated with current statin prescription. Adjusted for sex, cardiac risk, 
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Table 2 10- year mortality probabilities for non- statin prescription, and the absolute risk reduction (ARR) and relative risk 
reduction (RRR) in all- cause mortality associated with current statin prescription by risk profiles, presented in percentages
Men No statins Statins Statins





65 <20 7% 0.86/12.62 1.60/23.36
20–40 8% 0.96/12.57 1.77/23.28
≥40 or CVD 10% 1.24/12.43 2.29/23.06
70 <20 13% 1.62/12.73 3.46/27.14
20–40 14% 1.79/12.63 3.83/26.98
≥40 or CVD 20% 2.40/12.27 5.14/26.34
75 <20 NA NA NA
20–40 25% 4.96/19.56 7.25/28.58
≥40 or CVD 34% 6.34/18.56 9.32/27.29
80 <20 NA NA NA
20–40 24% 5.74/23.95 8.21/34.27
≥40 or CVD 30% 7.01/23.15 10.08/33.28
Profile B
65 <20 37% 3.93/10.53 7.44/19.93
20–40 41% 4.17/10.26 7.91/19.48
≥40 or CVD 50% 4.71/9.46 9.03/18.13
70 <20 49% 4.86/9.91 10.80/22.04
20–40 53% 5.05/9.52 11.30/21.30
≥40 or CVD 66% 5.33/8.11 12.24/18.62
75 <20 NA NA NA
20–40 69% 9.11/13.20 13.93/20.18
≥40 or CVD 81% 8.35/10.28 13.12/16.15
80 <20 NA NA NA
20–40 60% 11.04/18.29 16.41/27.18
≥40 or CVD 70% 11.30/16.04 17.09/24.26
Women No statins Statins Statins





65 <20 5% 0.67/12.71 1.23/12.37
20–40 6% 0.74/12.68 1.37/12.34
≥40 or CVD 8% 0.96/12.57 1.78/12.25
70 <20 10% 1.29/12.90 2.74/16.71
20–40 11% 1.43/12.83 3.04/16.63
≥40 or CVD 15% 1.93/12.55 4.14/16.33
75 <20 20% 4.03/20.12 5.86/11.49
20–40 20% 4.07/20.10 5.93/11.48
≥40 or CVD 28% 5.33/19.31 7.80/11.09
80 <20 NA NA NA
20–40 19% 4.69/24.52 6.69/13.84
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the question what the overall benefit is of statin uptake 
compared with never uptake.
The study also found that the mortality reductions asso-
ciated with current statin prescription differed by birth 
cohort, where people born in later years had greater 
benefits. This could be explained by the changing avail-
ability and recommended dosages of statin types resulting 
in more effective treatment over time, such as the with-
drawal of cerivastatin from the world market in 2001 
due to harmful effects.21 There were no other mortality 
differences associated with statin therapy, including no 
interaction with sex and cardiac risk. This translated to 
similar relative gains from statins across risk levels and 
profiles, yet the greatest absolute gains were seen in those 
at greatest risk.
Individuals taking statins could experience side effects 
of which diabetes could potentially have long- term conse-
quences for health.33 The most important outcome, 
however, is overall survival, which directly tallies up the 
benefits and harms of treatment. This is especially true 
for older people, where preventative treatments should 
not be focused on altering the cause of death but on 
prolonging life.6 This study showed that the incidence 
rate of diabetes was higher among participants with 
prior statin prescription compared with those without, 
however, current statin prescription was associated with 
mortality reductions irrespective of diabetes diagnosis 
and from age 70 years onward participants with a current 
statin prescription and diagnosis of diabetes had better 
overall survival prospects than those without a prescrip-
tion and no diagnosis.
This study was designed to address the current gap in 
clinical guidelines internationally on the uptake of statin 
therapy for primary and secondary prevention of CVD in 
older people, particularly those aged 75 years or older 
who do not have a history of CVD. Based on 1.8 million 
person- years of routinely collected primary care data, 
this study estimated and updated biyearly the long- term 
survival prospects associated with current statin therapy 
by incorporating participants’ time- varying prescription, 
cardiac risk and health status from age 60 to 85 years. The 
resulting dynamic risk model reflects clinical practice 
where sequential treatment decisions are made based on 
the patient’s health status over the life course and thereby 
predicts future health status more accurately compared 
with a static risk model.34
In this study, the survival effects of statin therapy 
were approximated by current statin prescription. This 
intention- to- treat analysis, however, could give conser-
vative treatment effects when there is lower actual 
uptake than observed prescription, low adherence in 
the treatment group and/or initiation of treatment 
in the control group.35 The purpose of the landmark 
approach for survival models is to capture the develop-
ment over time including changing treatment28 and our 
study showed minimal crossover of treatment arms. In 
the case of conservative treatment effects, it means that 
statin therapy is associated with even greater reductions 
in mortality as was estimated in our sensitivity analysis. 
On the other hand, there could be a healthy user bias 
in which individuals who are prescribed statins have a 
healthier lifestyle compared with those who do not and 
Men No statins Statins Statins
65 <20 30% 3.32/11.09 6.24/10.99
20–40 33% 3.56/10.88 6.71/10.81
≥40 or CVD 41% 4.18/10.25 7.94/10.26
70 <20 40% 4.32/10.67 9.50/14.30
20–40 44% 4.57/10.36 10.10/13.95
≥40 or CVD 56% 5.17/9.19 11.63/12.66
75 <20 59% 8.89/15.04 13.40/8.97
20–40 60% 8.91/14.96 13.44/8.93
≥40 or CVD 73% 9.03/12.44 13.90/7.66
80 <20 NA NA NA
20–40 51% 10.25/20.00 15.04/11.69
≥40 or CVD 61% 11.09/18.13 16.50/10.80
Profile A: healthiest and wealthiest profile included non- smokers without a diagnosis of diabetes, hypertension, 
hypercholesterolemia, or chronic kidney disease, and resident in the least deprived area.
Profile B: least healthy and wealthy profile included smokers with a diagnosis of diabetes, untreated hypertension, and 
resident in the most deprived area.
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in turn better survival prospects.36 This effect is well docu-
mented with statins in observational studies and would 
result in overestimated treatment effects.36 However, even 
propensity score matched analyses that deals with healthy 
user bias have reported significant reductions in mortality 
associated with statin therapy in people aged 75 years and 
older.37
Another limitation of an observational study is the 
possibility of confounding by indication. We attempted 
to minimise this by adjusting the regression analyses for 
known confounders of the effect of statin therapy associ-
ated with survival prospects, including cardiac risk and 
related comorbidities and treatments. Finally, although 
there were missing data, they were appropriately dealt 
with by multiple imputations and had very similar results 
as the complete case analysis.
Limited research exists on the overall benefit of statin 
in older people for long- term use. The influential CTT 
meta- analysis included from 19 out of 28 RCTs 8043 and 
6449 participants with and without a history of CVD, 
respectively, who were older than 75 years and on average 
78.8 years at baseline.9 The median follow- up of the RCTs 
was almost 5 years, but this included all ages and there was 
very likely shorter follow- up at the older ages. The current 
STAREE statin trial aims to have 18 000 participants aged 
70 years or older without a history of CVD and follow 
them up for a 5- year treatment period.13 In contrast, our 
study included 15 761 and 62 967 participants with and 
without a history of CVD at age 75, and these numbers 
were 8457 and 22 710 at age 80. Our median follow- up 
was over 15 years, although this was almost 5 years at 
age 75, 3 years at age 80, and 1 year at age 85, neverthe-
less landmarking analysis allows to confidently predict 
survival prospects beyond the study period.28 The CTT 
meta- analysis included RCTs with strict inclusion criteria 
that limit the generalisability to the general population 
and fitted a static model with no updated statin exposure. 
Our modelling process with updated statin exposure and 
survival predictions are more sensitive to age differences 
and could be more useful in clinical practice, where 
patients come to clinicians at any age and multiple times. 
Furthermore, the CCT meta- analysis reported risk ratios 
as per mmol/L reduction in LDL (‘bad cholesterol’), 
making it difficult to compare results. Finally, they did 
not distinguish between statin therapy for primary or 
secondary prevention, whereas our study did and found 
that the extent of mortality reduction was not significantly 
different for primary and secondary prevention of CVD.
Other observational studies reported that statin therapy 
for primary prevention of CVD was associated with reduc-
tions in all- cause mortality in a population of aged 75 
or older in the USA,37 in Korea,16 in the UK if at high 
cardiac risk,15 and in Spain if in presence of diabetes,25 
and discontinuation of statins in 75 years is associated 
with increased risk of a first cardiac event.38 Our findings 
add to the evidence base that statins are not only benefi-
cial at a static moment but can be initiated and continued 
at older ages with long- term survival benefits.
CONCLUSIONS
Our study showed significant absolute and relative reduc-
tions in all- cause mortality associated with statins for 
primary and secondary prevention of CVD at all ages over 
65 years, including those at age 75 or older, in routine 
clinical practice over 25 years. This supports the use of 
statins, where clinically indicated and after discussion of 
the potential risks and benefits with the patient, in those 
aged over 75 years.
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